Ripretinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 173 publications
Efficacy of ripretinib in advanced gastrointestinal stromal tumor and treatment options after resistance: a retrospective real-world study
Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Published: September 07, 2026
Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 11, 2026
Why precision oncology works: lessons from gastrointestinal stromal tumours.
Journal: Exploration of targeted anti-tumor therapy
Published: March 13, 2026
A phase II study of cabozantinib in metastatic or unresectable refractory gastrointestinal stromal tumour(GIST): a single-centre study from India.
Journal: BMC cancer
Published: February 18, 2026
Quantification of buparlisib in human liver microsomes employing an ultra-fast, sensitive UPLC-MS/MS method: in vitro and in silico metabolic stability evaluation.
Journal: The Analyst
Published: January 27, 2026
Moving beyond a tale of two genes: Strides in management of metastatic gastrointestinal stromal tumors and their supportive care.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: December 28, 2025
Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition.
Journal: The American journal of pathology
Published: November 11, 2025
Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.
Journal: Journal of gastroenterology and hepatology
Published: October 19, 2025
Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to larotrectinib in GIST with NTRK fusion: a case report.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: September 15, 2025
Last Updated: 09/26/2026